All Resources

Access to Medicine • July 06, 2022

Developing a Pan-Canadian Genomics Strategy: Innovative Medicines Canada Response

Learn more|View

Access to Medicine • February 12, 2022

Optimizing Patient Access to Precision Therapies: Preparing for the Emerging Era of Advanced Testing

Learn more|View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more|View

Access to Medicine • November 15, 2021

Research Note: Oncology Clinical Trials: Canada Within the International Context

Clinical trials provide Canadian oncology patients with earlier access to new, innovative cancer treatments. But changes pending to the PMPRB will make the Canadian pharmaceutical market less attractive for investment….

Learn more|View

Drugs for Rare Diseases (DRD) • September 15, 2021

Addendum to IMC Submission on Drugs for Rare Diseases

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • June 21, 2021

Proposed Guidelines Monitoring and Evaluation Plan

Learn more|View

Economic Impact • May 30, 2021

The Canadian Research and Development Pharmaceutical Sector

Learn more|View

Access to Medicine • May 18, 2021

Clinical Trials in Canada – Numbers

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • May 04, 2021

Letter to the Honourable Patty Hajdu

Learn more|View

Access to Medicine • March 31, 2021

Making Canada an International Life Sciences Leader

Learn more|View

Drugs for Rare Diseases (DRD) • March 26, 2021

Towards a Value-based and Pan-Canadian Rare Disease Strategy

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • November 06, 2020

House of Commons Standing Committee on Health (HESA)

Learn more|View